Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
TEVA PHARMACEUTICAL INDUSTRIES (NY: TEVA)
56.40 USD  -0.11 (-0.19%)
Official Closing Price  /  Updated: 6:40 PM EST, Mar 6, 2015  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 3,494,861
Open 56.49
Bid (Size) 55.80 (100)
Ask (Size) 56.80 (200)
Prev. Close 56.51
Today's Range 55.79 - 56.58
52wk Range 47.36 - 61.90
Shares Outstanding 851,871,888
Dividend Yield 2.40%
Performance
YTD
+0.32%
+0.32%
1 Month
-2.64%
-2.64%
3 Month
-1.02%
-1.02%
6 Month
+7.39%
+7.39%
1 Year
+14.42%
+14.42%
Top News
More News
Teva to Present at the Barclays Global Healthcare Conference
from Business Wire News Releases
Teva Announces Sale of Sellersville, PA Facility
from Business Wire News Releases
More News
Read More
Who’s Next In The Pharma Buyout Boom?
category Hospira Inc/ , AstraZeneca plc (ADR) , NYSE:AZN , and 7 more.
from ETF DAILY NEWS
Teva Announces Early Results of Debt Tender Offer, Pricing, Election of Early Settlement and Increase in Maximum Amount and Priority 2 Notes Tender Cap
from Business Wire News Releases
Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed
from PR Newswire
Teva to Present at the Cowen & Company 35th Annual Healthcare Conference
from Business Wire News Releases
Teva Announces FDA Acceptance for Review of NDA for its Investigational Twice-Daily Hydrocodone Bitartrate Extended-Release Tablets with Proprietary Abuse Deterrence Technology
from Business Wire News Releases
Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints
from Business Wire News Releases
The Lancet Respiratory Medicine and AAAAI Publish Positive Data from Phase III Trials of Teva’s Reslizumab for the Treatment of Moderate to Severe Asthma in Patients with Elevated Blood Eosinophils
from Business Wire News Releases
BRIEF-U.S. judge for Teva in patent litigation concerning Atelvia
category companyNews
from Reuters: Company News
U.S. judge denies Ranbaxy bid to reinstate approvals for Valcyte, Nexium copies
category companyNews
from Reuters: Company News
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here